Flores-Hernández Sergio
Mexico
Research Article
Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial
Author(s): Banda-Lara Marco Isaac, Martínez-García María del Carmen, Vázquez-Rosales José Guillermo, Rendón-Macías Mario Enrique, Flores-Hernández Sergio, Rivera-Benítez César, Santos-González Margarito and Carrillo-Avalos BlancaBanda-Lara Marco Isaac, Martínez-García María del Carmen, Vázquez-Rosales José Guillermo, Rendón-Macías Mario Enrique, Flores-Hernández Sergio, Rivera-Benítez César, Santos-González Margarito and Carrillo-Avalos Blanca
Background: The use of antiretroviral therapy (ART) reduces both mortality and morbidity of patients with HIV/ AIDS. The effects of chloroquine against HIV replication are widely known.
Objective: To demonstrate that beginning HIV treatment with ART (tenofovir/emtricitabine/efavirenz) + chloroquine increases by at least 20% the proportion of patients with viral load (VL) <50 copies/mL and >200 CD4+/mcL compared to patients receiving only ART at six months follow up.
Method: A randomized double-blind clinical trial was performed in 95 patients at the Infectious Diseases Department of the Hospital General de Mexico diagnosed with HIV/AIDS classification C3 before their first ART: 48 patients in the ART + placebo group and 47 in the ART + chloroquine group.
Results: A .. View More»
DOI:
10.4172/2329-6887.1000182